Business Context and Reporting Period
Company: Lucid Diagnostics Inc. (LUCD)
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2023
Reporting Period: The filing primarily details a material definitive agreement entered into on March 13, 2023. It also references the announcement of financial results for the fiscal year ended December 31, 2022, via a press release incorporated by reference.
Key Financial Metrics and Transaction Details
This filing focuses on a private placement financing transaction rather than standard quarterly financial statements. Key metrics include:
- Transaction Type: Sale of Senior Secured Convertible Notes in a private placement.
- Principal Amount: Up to $11,111,110.
- Net Proceeds: Estimated at approximately $9.8 million after deducting a 10% original issue discount and estimated expenses.
- Interest Rate: 7.875% per annum.
- Maturity: Two years from issuance (subject to extension).
- Conversion Price: Initial fixed price of $5.00 per share.
- Liquidity Covenant: The Company must maintain available cash of at least $5 million at all times.
- Market Cap Covenant: The ratio of outstanding note principal/interest to average market capitalization (10-day) must not exceed 30%.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement (SPA) with an accredited investor. Key terms and changes include:
- Security and Guaranty: The Note is secured by all existing and future assets of the Company and its significant subsidiaries. Obligations are guaranteed by all subsidiaries.
- Amortization: Principal repayment occurs via monthly installments starting six months after issuance. Payments can be made in cash (at 115% of the installment amount) or in stock (at 100% of the installment amount).
- Stockholder Approval Requirement: The Company must hold a stockholder meeting by July 31, 2023, to approve an increase in authorized common stock from 100 million to 200 million shares to facilitate conversions under Nasdaq rules.
- Voting Agreement: Parent company PAVmed Inc. (holding ~72% of common stock) agreed to vote in favor of the required stockholder resolutions.
- Participation Rights: The investor receives rights to participate in future equity or debt offerings for up to three years, up to 100% of the securities sold.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing incorporates a press release regarding fiscal year 2022 results but does not provide specific forward-looking guidance or commentary within the text of this 8-K. The transaction is intended to provide capital, with closing expected on or about March 21, 2023.
Risks and Contingencies:
- Events of Default: Includes failure of key executives (CEO Lishan Aklog, M.D., and CFO Dennis McGrath) to serve in their roles, breach of covenants, or failure to maintain financial ratios.
- Redemption Penalties: Upon an Event of Default, the Company may be required to redeem the Note at 132.5% of the conversion amount or a value based on the highest stock price since the default event.
- Change of Control: Triggers a redemption right at 115% of the greater of the outstanding value or the underlying share value.
- Beneficial Ownership Limitation: Conversion is limited if the holder would own more than 9.99% of outstanding shares (unless increased with notice).
- Nasdaq Limitation: Issuance of shares upon conversion is capped at 19.99% of outstanding shares unless stockholder approval is obtained.
Important Facts for Investor Verification
- Verify the closing of the transaction and the actual net proceeds received, as the $9.8 million figure is an estimate.
- Monitor the Company's ability to maintain the $5 million minimum cash covenant and the 30% debt-to-market-cap ratio.
- Confirm the scheduling and outcome of the stockholder meeting required by July 31, 2023, to increase authorized shares.
- Review the full text of the press release (Exhibit 99.1) for specific fiscal year 2022 revenue, profit, and cash flow figures, as this 8-K does not contain those numbers.
- Assess the impact of the 10% original issue discount and the potential for significant dilution given the $5.00 conversion price and installment conversion mechanics.